UBS Group
ONCO icon

UBS Group’s Onconetix ONCO Stock Holding History

UBS Group’s Portfolio ONCO Stock Details ONCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-158
Closed -$2.35K – 10866
2026
Q1 		$2.35K Sell
158
-26
-14% -$1.35K ﹤0.01% 9296
2025
Q4 		$14.4K Buy
184
+74
+67% +$10.2K ﹤0.01% 8013
2025
Q3 		$17.1K Buy
110
+54
+96% +$9.1K ﹤0.01% 8258
2025
Q2 		$13.3K Buy
56
+55
+5,500% +$16.1K ﹤0.01% 8701
2025
Q1 		$425 Sell
1
-1
-50% -$1.72K ﹤0.01% 9783
2024
Q4 		$5.47K Sell
2
-1
-33% -$10.1K ﹤0.01% 8658
2024
Q3 		$67.5K Buy
+3
New +$72K ﹤0.01% 6627
2024
Q2 		– Hold
0
– -$554 – 9937
2024
Q1 		– Hold
0
– – – 8477
2023
Q4 		– Hold
0
– – – 8719
2023
Q3 		– Hold
0
– -$1.7K – 9830
2023
Q2 		– Hold
0
– – – 7869
2023
Q1 		– Hold
0
– -$2.9K – 10147
2022
Q4 		– Hold
0
– – – 9606
2022
Q3 		– Hold
0
– -$7K – 10751
2022
Q2 		– Hold
0
– – – 8510
2022
Q1 		– Hold
0
– – – 6580

Other funds holding ONCO

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's ONCO Position: Q2 2026 in Review

UBS Group sold out of Onconetix (ONCO) in Q2 2026, closing a stake of 158 shares — an estimated $2.35K sold.

UBS Group first reported a position in ONCO in Q3 2024 and held it in 7 quarters. The position peaked at $67.5K in Q3 2024. 6 funds tracked by Wall St. Rank hold ONCO as of Q2 2026.

  • UBS Group reported no remaining Onconetix position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 158 Onconetix shares in Q2 2026, an estimated $2.35K.
  • UBS Group first reported a position in Onconetix in Q3 2024 and held it in 7 quarters.
  • UBS Group's Onconetix position peaked at $67.5K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Onconetix as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.